WASHINGTON, D.C.—The American Pharmacists Association (APhA) is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that results in improved workplaces, well-being, and the ability to meet ethical obligations to patient safety. 

WASHINGTON, DC and BESSEMER, AL—Plan sponsors and PBMs who manage prescription drug benefits under Medicare Part D are shifting costs and risks to America’s seniors and taxpayers by artificially inflating prescription drug costs at the pharmacy counter, according to a groundbreaking new study released today.

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to the FTC’s stalemate 2-2 vote today, which would have supported study of the competitive impact of contractual provisions, reimbursement adjustments, and other PBM practices affecting drug prices, including those practices that may disadvantage independent or specialty pharmacies.

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement to congratulate Robert Califf, MD, on his confirmation to serve once again as commissioner of FDA. APhA looks forward to working with both Califf and the FDA to ensure the safety, efficacy, and security of medications for our nation’s pharmacy patients.

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to plans and payers, including PBMs, setting the dispensing fee for new COVID‐19 oral antiviral therapies below pharmacies’ costs to dispense these lifesaving medications: